期刊
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
卷 38, 期 2, 页码 125-128出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JCP.0000000000000841
关键词
minocycline; inflammation; schizophrenia; glucose; lipids
资金
- Research Fund from Yunnan Province, China [2014NS147]
Purpose/Background This study examined the effect of adjunctive minocycline on body metabolism in risperidone-treated patients with schizophrenia. Methods/Procedures Each subject had a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of schizophrenia and had been on stable dose of risperidone for at least 4 weeks. In a 16-week randomized, double-blind, placebo-controlled study, subjects received either minocycline (200 mg/d) or placebo. Various metabolic parameters, including weight, waist circumference, fasting insulin, glucose, and lipids, were measured at baseline and week 16. Findings/Results A total of 63 subjects with schizophrenia were enrolled in the study. Fifty-five patients completed week-16 assessments (27 in the minocycline group, 28 in the placebo group). There were no significant differences between the 2 groups in week 16 changes for body weight, body mass index, waist circumference, fasting insulin, glucose, and lipids (P's > 0.300). Implications/Conclusions In the present study, adjunctive treatment of minocycline did not seem to improve body metabolism in patients with schizophrenia receiving risperidone. The implications for future studies were discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据